Avenue Therapeutics, Inc. - ATXI STOCK NEWS

Avenue Therapeutics (Nasdaq: ATXI) announced participation in a Type C meeting with the FDA on March 9, 2023, to discuss a study protocol assessing respiratory depression risks from IV Tramadol. The company aims to finalize this protocol based on feedback from a prior meeting on August 9, 2022, where the FDA approved the proposed study design. Additionally, on March 7, 2023, CEO Alexandra MacLean was appointed to the Board, and Dr. Jay Kranzler became Chairman. The company will hold its 2023 Annual Meeting on June 22, 2023, with stockholders needing to submit proposals by March 24, 2023.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) has announced an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. for AJ201, a first-in-class therapy in clinical trials for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease. This rare disease currently lacks FDA-approved treatments. The agreement involves an upfront payment of $3 million and equity issuance, with potential royalties on net sales. AJ201 has received Orphan Drug Designation and is part of a Phase 1b/2a trial in the U.S. aimed at assessing its safety and effectiveness. The company views this asset as pivotal for enhancing its therapeutic portfolio.

Aegis Capital Corp. has successfully facilitated a $3.25 million registered direct and private placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). Avenue Therapeutics focuses on developing therapies for central nervous system diseases and is headquartered in Miami, Florida. The company was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). This funding aims to bolster Avenue Therapeutics’ pipeline and support its growth strategy. For more details, visit Avenue Therapeutics.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) recently closed a registered direct offering and private placement with an institutional investor, raising approximately $3.25 million. The company issued 1,940,299 shares of common stock at a purchase price of $1.55 per share, alongside warrants with an exercise price also set at $1.55. The gross proceeds from this transaction will be directed towards general corporate purposes and working capital. Notably, these transactions comply with Nasdaq regulations, ensuring all offerings are priced appropriately.

Avenue Therapeutics (Nasdaq: ATXI) has entered into a definitive agreement with an institutional investor for a registered direct offering of 1,940,299 shares of common stock and pre-funded warrants. Concurrently, the company will issue the same investor 1,940,299 warrants, each with an exercise price of $1.55. The projected gross proceeds from these transactions amount to approximately $3.25 million, expected to close by January 31, 2023. The shares and warrants are priced at $1.55 and $0.125, respectively. Avenue plans to use the net proceeds for general corporate purposes and working capital.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) reported Q3 2022 financial results, achieving key milestones in drug development for CNS diseases. The company had a fruitful FDA meeting regarding IV Tramadol, indicating a path for NDA resubmission, and it completed the acquisition of Baergic Bio, adding a novel therapy to its portfolio. Financially, Avenue's cash position decreased to $0.2 million as of September 30, 2022, but improved with $10.4 million from a public offering. The net loss was $0.7 million with a reduced loss per share of $0.45.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the acquisition of Baergic Bio, a clinical-stage company focused on CNS disorders. This acquisition aims to enhance Avenue's portfolio with BAER-101, a selective GABA-A α2/3 receptor positive allosteric modulator in development as a treatment for various CNS conditions. The acquisition aligns with Avenue's strategy to address unmet needs in CNS therapeutics and is expected to strengthen its market position following its recent capital raise.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) successfully completed a $12 million underwritten public offering, with Aegis Capital Corp. serving as the sole bookrunner on October 12, 2022. The funds raised will support the company's development of intravenous Tramadol, a dual-acting opioid currently in Phase III trials for treating post-operative acute pain. Avenue Therapeutics focuses on specialty pharmaceuticals for acute care settings and was incorporated in 2015.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the closing of its public offering of 3,636,365 common and pre-funded units at a price of $3.30 per unit, raising approximately $10.4 million after expenses. The capital will be used to repurchase shares held by InvaGen Pharmaceuticals Inc. and for general corporate purposes, including drug development. An additional 545,454 warrants were sold via an over-allotment option. Aegis Capital Corp. managed the offering, with all operations in compliance with SEC regulations.